JP2016041701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016041701A5 JP2016041701A5 JP2015193990A JP2015193990A JP2016041701A5 JP 2016041701 A5 JP2016041701 A5 JP 2016041701A5 JP 2015193990 A JP2015193990 A JP 2015193990A JP 2015193990 A JP2015193990 A JP 2015193990A JP 2016041701 A5 JP2016041701 A5 JP 2016041701A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ethoxybenzyl
- triol
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 claims 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Claims (11)
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶及び薬学的に許容される賦形剤を含む医薬組成物。
- 錠剤、カプセル、又はカプレットの形態である、請求項1に記載の医薬組成物。
- アテローム性動脈硬化症、循環器疾患、糖尿病、高血糖、高血圧、脂質障害、肥満、又はX症候群の治療又は管理用である、請求項1又は2に記載の医薬組成物。
- 糖尿病の治療又は管理用である、請求項1〜3のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、124℃±5.0℃にDSC吸熱を有する、請求項1〜4のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、4.0°、8.1°、9.8°、14.0°及び/又は19.3°の2θ±0.3度のうちの1つ又は複数のピークを有するX線粉末回折パターンを有する、請求項1〜4のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、14.0°の2θ±0.3度のピークを有するX線粉末回折パターンを有する、請求項6に記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、3068cm −1 、2929cm −1 、2888cm −1 、2881cm −1 、1615cm −1 、1603cm −1 、1244cm −1 、1037cm −1 、692cm −1 及び/又は372cm −1 のうちの1つ又は複数のピークを有するラマンスペクトルを有する、請求項1〜4のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、134℃±5.0℃のDSC吸熱を有する、請求項1〜4のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、4.4°、4.8°、14.5°、14.7°、15.5°、21.2°、22.1°及び/又は23.8°の2θ±0.3度のうちの1つ又は複数のピークを有するX線粉末回折パターンを有する、請求項1〜4のいずれかに記載の医薬組成物。
- 無水(2S,3R,4R,5S,6R)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2H−ピラン−3,4,5−トリオールの結晶が、4.4°の2θ±0.3度のピークを有するX線粉末回折パターンを有する、請求項10に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8142308P | 2008-07-17 | 2008-07-17 | |
US61/081,423 | 2008-07-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518868A Division JP2011528366A (ja) | 2008-07-17 | 2009-07-15 | (2s,3r,4r,5s,6r)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2h−ピラン−3,4,5−トリオールの固体形態及びその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016041701A JP2016041701A (ja) | 2016-03-31 |
JP2016041701A5 true JP2016041701A5 (ja) | 2016-12-28 |
JP6283337B2 JP6283337B2 (ja) | 2018-02-21 |
Family
ID=41137707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518868A Pending JP2011528366A (ja) | 2008-07-17 | 2009-07-15 | (2s,3r,4r,5s,6r)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2h−ピラン−3,4,5−トリオールの固体形態及びその使用方法 |
JP2015193990A Active JP6283337B2 (ja) | 2008-07-17 | 2015-09-30 | (2s,3r,4r,5s,6r)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2h−ピラン−3,4,5−トリオールの固体形態及びその使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518868A Pending JP2011528366A (ja) | 2008-07-17 | 2009-07-15 | (2s,3r,4r,5s,6r)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2h−ピラン−3,4,5−トリオールの固体形態及びその使用方法 |
Country Status (29)
Country | Link |
---|---|
US (2) | US8217156B2 (ja) |
EP (1) | EP2332947B1 (ja) |
JP (2) | JP2011528366A (ja) |
KR (2) | KR101707246B1 (ja) |
CN (2) | CN107629097A (ja) |
AR (1) | AR072807A1 (ja) |
AU (1) | AU2009270973B2 (ja) |
BR (1) | BRPI0916191A2 (ja) |
CA (1) | CA2730931A1 (ja) |
CL (1) | CL2009001595A1 (ja) |
CO (1) | CO6351797A2 (ja) |
DK (1) | DK2332947T3 (ja) |
ES (1) | ES2656357T3 (ja) |
HK (1) | HK1243713A1 (ja) |
HU (1) | HUE035400T2 (ja) |
IL (1) | IL210269A (ja) |
MX (1) | MX2011000503A (ja) |
NO (1) | NO2332947T3 (ja) |
NZ (1) | NZ590184A (ja) |
PE (1) | PE20100260A1 (ja) |
PL (1) | PL2332947T3 (ja) |
PT (1) | PT2332947T (ja) |
RU (1) | RU2505543C2 (ja) |
SG (1) | SG185317A1 (ja) |
TW (1) | TWI472521B (ja) |
UA (1) | UA106048C2 (ja) |
UY (1) | UY31992A (ja) |
WO (1) | WO2010009197A1 (ja) |
ZA (1) | ZA201100175B (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
BRPI0813840A2 (pt) | 2007-07-26 | 2017-06-06 | Lexicon Pharmaceuticals Inc | métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio |
MX2011000637A (es) | 2008-07-15 | 2011-05-02 | Theracos Inc | Derivados deuretados de bencilbenceno y metodos de uso. |
TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
DK2925735T3 (da) * | 2012-11-20 | 2019-06-17 | Lexicon Pharmaceuticals Inc | Inhibitorer for natriumglucose-cotransporter 1 |
US20160272645A1 (en) | 2013-10-18 | 2016-09-22 | Medivation Technologies, Inc. | Heterocyclic Compounds and Methods of Use |
WO2015058084A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
JP6938376B2 (ja) | 2015-07-30 | 2021-09-22 | 公益財団法人微生物化学研究会 | 多剤耐性菌に有効な新規アミノグリコシド抗生物質 |
EP3466958B1 (en) * | 2016-05-25 | 2020-04-29 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof |
WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
EP3528800A1 (en) | 2016-10-19 | 2019-08-28 | Boehringer Ingelheim International GmbH | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
EP3781166A1 (en) | 2018-04-17 | 2021-02-24 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
JP2022502393A (ja) * | 2018-09-26 | 2022-01-11 | レクシコン ファーマシューティカルズ インコーポレイテッド | N−(1−((2−(ジメチルアミノ)エチル)アミノ)−2−メチル−1−オキソプロパン−2−イル)−4−(4−(2−メチル−5−((2s,3r,4r,5s,6r)−3,4,5−トリヒドロキシ−6−(メチルチオ)テトラヒドロ−2h−ピラン−2−イル)ベンジル)フェニル)ブタンアミドの結晶形態及びそれらの合成方法 |
EP3873599B1 (en) | 2018-10-29 | 2023-09-27 | Boehringer Ingelheim International GmbH | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
FI3873600T3 (fi) | 2018-10-29 | 2023-12-07 | Boehringer Ingelheim Int | Pyridinyylisulfonamidijohdannaisia, farmaseuttisia koostumuksia ja niiden käytöt |
CN109824687B (zh) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | 呋喃木糖衍生物的新合成方法 |
US20220324897A1 (en) * | 2019-07-05 | 2022-10-13 | Shandong Danhong Pharmaceutical Co., Ltd. | Crystal form of sglt inhibitor and application thereof |
EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
EP3771718A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
WO2022155303A1 (en) | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
JP2003519698A (ja) * | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
ATE445608T1 (de) | 2005-02-23 | 2009-10-15 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2) |
CN1820858A (zh) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | 多相物料喷雾方法及装置 |
TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
BRPI0813840A2 (pt) * | 2007-07-26 | 2017-06-06 | Lexicon Pharmaceuticals Inc | métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio |
TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/zh active
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 BR BRPI0916191A patent/BRPI0916191A2/pt not_active Application Discontinuation
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/ko active IP Right Grant
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/es not_active Application Discontinuation
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/ja active Pending
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/es active Active
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/zh not_active Withdrawn
- 2009-07-15 PL PL11155100T patent/PL2332947T3/pl unknown
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/ru active
- 2009-07-15 NZ NZ590184A patent/NZ590184A/xx unknown
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en active Application Filing
- 2009-07-15 UA UAA201101832A patent/UA106048C2/uk unknown
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 AR ARP090102685A patent/AR072807A1/es unknown
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/es unknown
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/da active
- 2009-07-15 PT PT111551008T patent/PT2332947T/pt unknown
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/ko not_active Application Discontinuation
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/es active IP Right Grant
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/zh active Pending
- 2009-07-16 UY UY0001031992A patent/UY31992A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/ja active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016041701A5 (ja) | ||
JP2015120736A5 (ja) | ||
NZ590184A (en) | Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use | |
JP2016065042A5 (ja) | ||
JP2015145426A5 (ja) | ||
JP2014526498A5 (ja) | ||
JP2014501780A5 (ja) | ||
JP2015044837A5 (ja) | ||
JP2013543867A5 (ja) | ||
RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
JP2012512885A5 (ja) | ||
WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
HRP20211834T1 (hr) | Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola | |
PH12013502274A1 (en) | L-proline and citric acid co-crystals of (2s, 3r, 4r, 5s, 6r)-2-(3-((5-(4-flourophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol | |
JP2017519027A5 (ja) | ||
PH12017501029A1 (en) | Biaryl derivative as gpr120 agonist | |
JP2015514797A5 (ja) | ||
NZ701702A (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
WO2011045232A3 (en) | Neuropeptide-2 receptor (y-2r) agonists | |
JP2012509281A5 (ja) | ||
RU2016141650A (ru) | Амидные соединения | |
RU2017137269A (ru) | Кристаллические формы 1-((2r,4r)-2-(1h-бензо[d]имидазол-2-ил)-1-метилпиперидин 4-ил)-3-(4-цианофенил)мочевины малеата |